![Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer]()
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerRimawi, Mothaffar F.; De Angelis, Carmine; Contreras, Alejandro; Pareja, Fresia; Geyer, Felipe C.; Burke, Kathleen A.; Herrera, Sabrina; Wang, Tao; Mayer, Ingrid A.; Forero, Andres; Nanda, Rita; Goetz, Matthew P.; Chang, Jenny C.; Krop, Ian E.; Wolff, Antonio C.; Pavlick, Anne C.; Fuqua, Suzanne A. W.; Gutierrez, Carolina; Hilsenbeck, Susan G.; Li, Marilyn M.; Weigelt, Britta; Reis-Filho, Jorge S.; Kent Osborne, C.; Schiff, Rachel · Breast Cancer Research and Treatment · 2017